Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Docetaxel vs FLOT in Gastric Cancer
NCT06313801Phase 2Recruiting
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
- Start
- Jan 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in gastric cancer (GC) (2 arms), sponsored by Nizhny Novgorod Regional Clinical Oncology Center. Primary endpoints: Progression-Free Survival and Complications from polychemotherapy. Started Jan 2023; status: recruiting.
02
Drugs
docetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06313801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313801.